BG
BPMC

BlackRock Group’s Blueprint Medicines BPMC Stock Holding History

BlackRock Group’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$154K Sell
5,495
-2,362
-30% -$71.2K ﹤0.01% 2733
2016
Q3 		$234K Buy
7,857
+865
+12% +$21.5K ﹤0.01% 2577
2016
Q2 		$141K Buy
6,992
+4,311
+161% +$78.3K ﹤0.01% 2681
2016
Q1 		$48K Buy
+2,681
New +$46.5K ﹤0.01% 2927
2015
Q3 		– Sell
-6,724
Closed -$178K – 3050
2015
Q2 		$178K Buy
+6,724
New +$192K ﹤0.01% 2613

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock Group's BPMC Position: Q4 2016 in Review

BlackRock Group reduced its Blueprint Medicines (BPMC) stake by 30% in Q4 2016, selling an estimated $71.2K and leaving 5,495 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #2733.

BlackRock Group first reported a position in BPMC in Q2 2015 and has held it in 5 quarters since. The position peaked at $234K in Q3 2016. 103 funds tracked by Wall St. Rank hold BPMC as of Q4 2016.

  • BlackRock Group held 5,495 shares of Blueprint Medicines worth $154K as of Q4 2016.
  • BlackRock Group sold 2,362 Blueprint Medicines shares in Q4 2016, an estimated $71.2K.
  • Blueprint Medicines made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2733 holding.
  • BlackRock Group first reported a position in Blueprint Medicines in Q2 2015 and has held it in 5 quarters since.
  • BlackRock Group's Blueprint Medicines position peaked at $234K in Q3 2016.
  • 103 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.